Key result
KK-Ay mouse serves as a useful spontaneous model for evaluating type 2 diabetic nephropathy therapies.
Why the study?
KK-Ay mice are considered a suitable spontaneous animal model for human type 2 diabetic nephropathy, but their utility for evaluating pathogenesis and treatment requires clarification.
The KK-Ay mouse serves as a valuable spontaneous model for studying the pathogenesis and evaluating treatments for human type 2 diabetic nephropathy.
Answers are grounded in this paper and cite their sources.
May accelerate preclinical testing of diabetic nephropathy therapies; leaves open translation to human care.
Diabetic nephropathy is a major cause of end-stage kidney disease (ESKD) in patients with type 1 and type 2 diabetes throughout the world. In human glomeruli, expansion of diffuse mesangial matrices, exudative lesions and/or segmental nodular sclerosis are pathological features of diabetic nephropathy. There have been many reports on the pathogenesis and treatment of type 2 diabetes using various animal models. It appears that KK-Ay mice, especially in terms of their immunohistological findings, are a suitable animal model for human type 2 diabetic nephropathy. Many compounds have been reported to be advanced glycation end product (AGE) inhibitors such as aminoguanidine, angiotensin II receptor inhibitors and pyridoxamine, and these are useful in therapeutic interventions for reducing AGEs. Pyridoxamine ameliorates lipid peroxidation and insulin resistance in KK-Ay mice. Combination therapy with angiotensin converting inhibitors (ACE-I) and angiotensin II type 1 receptor blockers (ARB), including an ARB and 1,25-dihydroxyvitamin D3, i.e. anti-hypertensive and anti-reactive oxygen species effects, or with eicosapentaenoic acid (EPA), i.e. anti-microinflammation effect, have shown efficacy in the treatment of diabetic nephropathy in KK-Ay mice. It appears that KK-Ay mice are a useful spontaneous animal model for the evaluation of pathogenesis and treatment in patients with type 2 diabetic nephropathy.
No takes yet. Share an insight, caveat, or question.
Yasuhiko Tomino (2012) conducted a review in Type 2 Diabetic Nephropathy. Various treatments (pyridoxamine, ACE-I, ARB, EPA) was evaluated. The KK-Ay mouse serves as a useful spontaneous animal model for evaluating the pathogenesis and potential treatments for human type 2 diabetic nephropathy.
Synapse has enriched 10 related papers. Consider them for comparative context: